Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities - Seite 2

Launched in 2021, the Gilead Zeroing In grant program provides support to organizations whose programs aim to increase the overall health and wellness of communities most impacted by HIV.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead’s medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

About the Gilead Zeroing In Grant Program

Zeroing In builds on previous Gilead funding and grant programs, while supporting organizations to increase the overall health and wellness of communities most impacted by HIV and COVID-19. Gilead provides support to organizations whose programs align with international and country-specific goals of the Ending the HIV Epidemic initiative. This includes local community programming and coalition-led proposals from organizations collaborating to end the HIV epidemic in their respective city, state, country or region. Zeroing In programming focuses on comprehensive HIV innovation, digital health innovation, and/or community outreach and education.

For more information on Gilead’s Zeroing In grant program to help end the HIV epidemic, please visit https://www.gilead.com/purpose/giving/zeroing-in-ending-hiv-epidemic.

GILEAD, the GILEAD Logo, ZEROING IN and COMPASS INITIATIVE are trademarks of Gilead Sciences, Inc.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005679/en/

The Gilead Sciences Stock at the time of publication of the news with a fall of -0,52 % to 78,73USD on Nasdaq stock exchange (22. März 2023, 16:35 Uhr).